Diagnosis and treatment of polycythemia vera
Brazilian experience from a single institution
Keywords:
Polycythemia vera, Treatment outcome, Thrombosis, Survival, BrazilAbstract
CONTEXT AND OBJECTIVE: Polycythemia vera (PV) is a chronic myeloproliferative disorder characterized by predominant proliferation of erythroid precursors. Few data are available concerning Brazilian patients with this condition. The aim of this study was to describe clinical and demographic characteristics of PV patients at diagnosis and analyze their long-term outcomes. DESIGN AND SETTING: Retrospective study at the Division of Hematology, Faculdade de Medicina da Universidade de São Paulo (FMUSP), São Paulo. METHODS: All consecutive patients with PV diagnosed according to World Health Organization criteria were eligible for this study. Clinical and demographic characteristics, thrombotic events, transformation to acute leukemia, myelofibrosis and survival were evaluated. RESULTS: Sixty-six patients were evaluated. Thirtysix (54.5%) were females, with a median age at diagnosis of 61 years. At diagnosis, the median hemoglobin concentration was 18.8 mg/dl and the median platelet count was 593,000/mm3. Fifty-eight patients (88.0%) were treated with hydroxyurea with or without phlebotomy. During a median follow-up of 77 months, 22 patients (33.3%) had new thrombotic events, mainly of arterial type. The overall incidence of leukemia and myelofibrosis was 0.42% per patient-year and 1.06% per patient-year, respectively. Median overall survival was not reached and the seven-year survival rate was 77.8%. CONCLUSION: The PV patients described here had long survival and arterial thrombotic events were the most important and common complication among this population.
Downloads
References
Berlin NI. Diagnosis and classification of the polycythemias. Semin Hematol. 1975;12(4):339-51.
Pierre R, Imbert M, Thiele J, Vardiman JW, Brunning RD, Frandrin G. Polycythemia vera. In: Jaffe ES, Harris NL, Stein H, Vardiman JW, editors. World Health Organization (WHO) Classification of Tumors: Pathology and Genetics of Tumors of Haematopoietic and Lymphoid Tissues. Lyon: IARC Press; 2001. p. 32-4.
Berk PD, Goldberg JD, Donovan PB, Fruchtman SM, Berlin NI, Wasserman LR. Therapeutic recommendations in polycy- themia vera based on Polycythemia Vera Study Group protocols. Semin Hematol. 1986;23(2):132-43.
Finazzi G, Caruso V, Marchioli R, et al. Acute leukemia in polycythemia vera: an analysis of 1638 patients enrolled in a prospective observational study. Blood. 2005;105(7):2664-70.
Berk PD, Goldberg JD, Silverstein MN, et al. Increased inci- dence of acute leukemia in polycythemia vera associated with chlorambucil therapy. N Engl J Med. 1981;304(8):441-7.
Gilbert HS. Historical perspective on the treatment of essential thrombocythemia and polycythemia vera. Semin Hematol. 1999;36(1 Suppl 2):19-22.
Fruchtman SM, Mack K, Kaplan ME, Peterson P, Berk PD, Was- serman LR. From efficacy to safety: a Polycythemia Vera Study group report on hydroxyurea in patients with polycythemia vera. Semin Hematol. 1997;34(1):17-23.
Passamonti F, Rumi E, Pungolino E, et al. Life expectancy and prognostic factors for survival in patients with polycythemia vera and essential thrombocythemia. Am J Med. 2004;117(10):755-61.
Spivak JL. The optimal management of polycythaemia vera. Br J Haematol. 2002;116(2):243-54.
Recommended methods for measurement of red-cell and plasma volume: International Committee for Standardization in Haematology. J Nucl Med. 1980;21(8):793-800.
Marchioli R, Finazzi G, Landolfi R, et al. Vascular and neoplastic risk in a large cohort of patients with polycythemia vera. J Clin Oncol. 2005;23(10):2224-32.
Green AR, Vassiliou GS, Curtin N, Campbell PJ. Management of the myeloproliferative disorders: distinguishing data from dogma. Hematol J. 2004;5(Suppl 3):S126-32.
Bench AJ, Pahl HL. Chromosomal abnormalities and molecu- lar markers in myeloproliferative disorders. Semin Hematol. 2005;42(4):196-205.
Najean Y, Rain JD, Dresch C, et al. Risk of leukaemia, car- cinoma, and myelofibrosis in 32P- or chemotherapy-treated patients with polycythaemia vera: a prospective analysis of 682 cases. The “French Cooperative Group for the Study of Polycythaemias”. Leuk Lymphoma. 1996;22(Suppl 1):111-9.
Berk PD, Wasserman LR, Fruchtman SM, Goldberg JD. Treat- ment of polycythemia vera: a summary of clinical trials conducted by the polycythemia vera study group. In: Wasserman LR, Berk PD, Berlin NI, editors. Polycythemia vera and myeloproliferative disorders. Philadelphia: WB Saunders; 1995. p. 166-94.
Andreasson B, Löfvenberg E, Westin J. Management of patients with polycythaemia vera: results of a survey among Swedish haematologists. Eur J Haematol. 2005;74(6):489-95.
Baxter EJ, Scott LM, Campbell PJ, et al. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet. 2005;365(9464):1054-61.
